In:
Drug Metabolism and Drug Interactions, Walter de Gruyter GmbH, Vol. 29, No. 4 ( 2014-01-1)
Abstract:
Spanning over 2000 years, the Jewish population has a long history of migration, population bottlenecks, expansions, and geographical isolation, which has resulted in a unique genetic architecture among the Jewish people. As such, many Mendelian disease genes and founder mutations for autosomal recessive diseases have been discovered in several Jewish groups, which have prompted recent genomic studies in the Jewish population on common disease susceptibility and other complex traits. Although few studies on the genetic determinants of drug response variability have been reported in the Jewish population, a number of unique pharmacogenetic variants have been discovered that are more common in Jewish populations than in other major racial groups. Notable examples identified in the Ashkenazi Jewish (AJ) population include the vitamin K epoxide reductase complex subunit 1 (
Type of Medium:
Online Resource
ISSN:
2191-0162
,
0792-5077
DOI:
10.1515/dmdi-2013-0069
Language:
Unknown
Publisher:
Walter de Gruyter GmbH
Publication Date:
2014
detail.hit.zdb_id:
2588286-7
detail.hit.zdb_id:
2822040-7
SSG:
15,3
Permalink